Inhibitor against coagulation factor V after liver transplantation.
A new case of anti-factor V inhibitor is described in a 46-year-old man, who received a liver transplantation for hepatocellular carcinoma, without exposure to bovine thrombin or fibrin glue during the operative course. The inhibition occurred on the 14th postoperative day, while the patient was being treated with oxacillin, azathioprine, and a new immunosuppressive drug, FK506. The inhibition was of short duration (3 days), and no bleeding complication occurred despite a very low plasmatic level of factor V activity and antigen (<5%). Plasma samples drawn after cessation of FK506 disclosed a dose-dependent inhibitory activity when alcoholic solutions of FK506 were exogeneously added; this suggests a possible role of the FK506 drug in the occurrence of this anti-factor V inhibitor.
Leroy-Matheron
C
C
Unité d'Hémostase et de Thrombose, Centre Hospitalier Universitaire Henri Mondor, Créteil, France.
Mallat
A
A
Duvoux
C
C
Métreau
J M
JM
Cherqui
D
D
Dhumeaux
D
D
Gouault-Heilmann
M
M
D006528:Carcinoma, Hepatocellular / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D005165:Factor V / Q000037:antagonists & inhibitors*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*
D007136:Immunoglobulins; D007166:Immunosuppressive Agents; C019158:circulating anticoagulants; D005165:Factor V; D016559:Tacrolimus